BRAF and melanoma: Pending further validation, the isoforms may support oncologist-patient decision-making in selecting a more aggressive treatment regime (for melanomas with elevated TAp53 and p53β for example) or support the rejection of chemotherapy or BRAF inhibition for melanomas with elevated Δ40p53, where the isoform may drive unfavourable treatment responses [31, 33, 61].